BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23443327)

  • 1. A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
    Masui Y; Asano Y; Shibata S; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
    Rheumatology (Oxford); 2013 Jul; 52(7):1239-44. PubMed ID: 23443327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis.
    Masui Y; Asano Y; Shibata S; Noda S; Aozasa N; Akamata K; Yamada D; Tamaki Z; Tada Y; Sugaya M; Sato S; Kadono T
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):354-60. PubMed ID: 21504484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progranulin Overproduction Due to Fli-1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor in Systemic Sclerosis.
    Ichimura Y; Asano Y; Akamata K; Noda S; Taniguchi T; Takahashi T; Toyama T; Tada Y; Sugaya M; Sato S; Kadono T
    Arthritis Rheumatol; 2015 Dec; 67(12):3245-55. PubMed ID: 26245842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.
    Noda S; Asano Y; Takahashi T; Akamata K; Aozasa N; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Rheumatology (Oxford); 2013 May; 52(5):790-9. PubMed ID: 23287360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
    Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
    Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.
    Khan K; Xu S; Nihtyanova S; Derrett-Smith E; Abraham D; Denton CP; Ong VH
    Ann Rheum Dis; 2012 Jul; 71(7):1235-42. PubMed ID: 22586157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
    Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating γ/δ T cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of proalpha2(I) collagen of fibroblasts.
    Ueda-Hayakawa I; Hasegawa M; Hamaguchi Y; Takehara K; Fujimoto M
    J Dermatol Sci; 2013 Jan; 69(1):54-60. PubMed ID: 23159281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
    Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
    Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.
    Carulli MT; Ong VH; Ponticos M; Shiwen X; Abraham DJ; Black CM; Denton CP
    Arthritis Rheum; 2005 Dec; 52(12):3772-82. PubMed ID: 16320328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
    Chizzolini C; Raschi E; Rezzonico R; Testoni C; Mallone R; Gabrielli A; Facchini A; Del Papa N; Borghi MO; Dayer JM; Meroni PL
    Arthritis Rheum; 2002 Jun; 46(6):1602-13. PubMed ID: 12115192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis.
    Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):37-42. PubMed ID: 22112232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis.
    Noda S; Asano Y; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    PLoS One; 2012; 7(2):e32272. PubMed ID: 22384200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis.
    Kudo H; Jinnin M; Asano Y; Trojanowska M; Nakayama W; Inoue K; Honda N; Kajihara I; Makino K; Fukushima S; Ihn H
    Arthritis Rheumatol; 2014 Jun; 66(6):1636-47. PubMed ID: 24470401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.